See more : Anglesey Mining plc (AYM.L) Income Statement Analysis – Financial Results
Complete financial analysis of ResMed Inc. (RMD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ResMed Inc., a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
- Runway Growth Finance Corp. – 7 (RWAYL) Income Statement Analysis – Financial Results
- Megaworld Corporation (MGAWF) Income Statement Analysis – Financial Results
- MCAN Mortgage Corporation (MAMTF) Income Statement Analysis – Financial Results
- People, Dreams & Technologies Group Co., Ltd. (9248.T) Income Statement Analysis – Financial Results
- Teo Seng Capital (7252.KL) Income Statement Analysis – Financial Results
ResMed Inc. (RMD)
About ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME)to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; and HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies. The company markets its products primarily to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.69B | 4.22B | 3.58B | 3.20B | 2.96B | 2.61B | 2.34B | 2.07B | 1.84B | 1.68B | 1.55B | 1.51B | 1.37B | 1.24B | 1.09B | 920.74M | 835.40M | 716.33M | 607.00M | 425.51M | 339.34M | 273.57M | 204.08M | 155.16M | 115.62M | 88.60M | 66.50M | 49.20M | 34.60M | 23.50M | 13.90M | 7.70M |
| Cost of Revenue | 2.03B | 1.87B | 1.55B | 1.36B | 1.24B | 1.07B | 978.03M | 864.99M | 772.22M | 667.52M | 565.19M | 573.80M | 547.78M | 501.82M | 436.87M | 366.93M | 341.65M | 331.84M | 230.10M | 150.65M | 122.60M | 100.48M | 70.83M | 50.38M | 30.74M | 24.80M | 19.40M | 17.70M | 15.70M | 10.70M | 5.90M | 2.90M |
| Gross Profit | 2.66B | 2.36B | 2.02B | 1.84B | 1.72B | 1.54B | 1.36B | 1.20B | 1.07B | 1.01B | 989.79M | 940.66M | 820.74M | 741.33M | 655.48M | 553.80M | 493.75M | 384.49M | 376.90M | 274.86M | 216.74M | 173.09M | 133.25M | 104.78M | 84.87M | 63.80M | 47.10M | 31.50M | 18.90M | 12.80M | 8.00M | 4.80M |
| Gross Profit Ratio | 56.67% | 55.78% | 56.57% | 57.53% | 58.09% | 58.95% | 58.21% | 58.15% | 58.00% | 60.24% | 63.65% | 62.11% | 59.97% | 59.63% | 60.01% | 60.15% | 59.10% | 53.68% | 62.09% | 64.60% | 63.87% | 63.27% | 65.29% | 67.53% | 73.41% | 72.01% | 70.83% | 64.02% | 54.62% | 54.47% | 57.55% | 62.34% |
| Research & Development | 307.53M | 287.64M | 253.58M | 225.28M | 201.95M | 180.65M | 155.15M | 144.47M | 118.65M | 114.87M | 118.23M | 120.12M | 109.73M | 92.01M | 75.20M | 63.06M | 60.52M | 50.11M | 37.22M | 30.01M | 26.17M | 20.53M | 14.91M | 11.15M | 8.50M | 6.50M | 5.00M | 3.80M | 2.80M | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 600.37M | 553.97M | 488.06M | 478.63M | 450.41M | 430.80M | 401.62M | 372.25M | 331.86M | 289.88M | 278.09M | 237.33M | 200.17M | 135.70M | 104.71M | 85.31M | 64.48M | 49.91M | 36.99M | 27.40M | 21.10M | 16.80M | 11.10M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -5.46M | -6.00M | 0.00 | 0.00 | 0.00 | -1.00M | -3.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 917.14M | 874.00M | 739.37M | 670.39M | 676.69M | 645.01M | 600.37M | 553.97M | 482.59M | 472.63M | 450.41M | 430.80M | 401.62M | 371.25M | 328.86M | 289.88M | 278.09M | 237.33M | 200.17M | 135.70M | 104.71M | 85.31M | 64.48M | 49.91M | 36.99M | 27.40M | 21.10M | 16.80M | 11.10M | 9.40M | 6.40M | 3.90M |
| Other Expenses | 110.75M | -5.71M | 31.08M | 31.08M | 30.09M | 74.94M | -8.54M | 4.10M | 4.96M | 6.25M | 884.00K | -2.19M | 8.46M | 10.15M | 8.04M | 7.06M | 9.79M | 6.90M | 7.09M | 1.37M | 500.00K | 0.00 | 104.67M | 0.00 | 6.25M | 4.60M | 3.70M | 2.60M | 1.30M | 600.00K | 300.00K | 200.00K |
| Operating Expenses | 1.34B | 1.20B | 1.02B | 926.75M | 908.73M | 900.60M | 801.90M | 745.01M | 625.17M | 596.16M | 578.37M | 585.83M | 525.33M | 473.40M | 412.10M | 359.99M | 348.40M | 294.33M | 244.47M | 167.09M | 131.38M | 105.85M | 184.06M | 61.06M | 51.73M | 38.50M | 29.80M | 23.20M | 15.20M | 10.00M | 6.70M | 4.10M |
| Cost & Expenses | 3.37B | 3.07B | 2.58B | 2.28B | 2.15B | 1.97B | 1.78B | 1.61B | 1.40B | 1.26B | 1.14B | 1.16B | 1.07B | 975.22M | 848.98M | 726.92M | 690.05M | 626.17M | 474.57M | 317.73M | 253.98M | 206.33M | 254.89M | 111.44M | 82.48M | 63.30M | 49.20M | 40.90M | 30.90M | 20.70M | 12.60M | 7.00M |
| Interest Income | 0.00 | 47.38M | 22.31M | 362.00K | 1.02M | 2.30M | 16.38M | 17.09M | 16.86M | 26.21M | 31.24M | 38.87M | 33.87M | 27.80M | 16.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 45.71M | 47.38M | 22.31M | 23.99M | 40.38M | 36.16M | 28.36M | 28.24M | 11.21M | 5.78M | 6.13M | 6.39M | 4.79M | 1.76M | 10.06M | 10.06M | 10.06M | 1.32M | 1.32M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 216.21M | 196.52M | 193.84M | 191.52M | 181.37M | 150.80M | 119.96M | 112.16M | 86.85M | 73.06M | 9.73M | 10.14M | 13.97M | 10.15M | 8.04M | 7.06M | 59.49M | 48.14M | 41.62M | 29.13M | 17.87M | 12.58M | 9.97M | 8.45M | 6.25M | 4.60M | 3.70M | 2.60M | 1.30M | 600.00K | 300.00K | 200.00K |
| EBITDA | 1.53B | 1.36B | 1.18B | 1.10B | 990.43M | 705.80M | 680.22M | 568.89M | 522.72M | 482.29M | 484.87M | 469.79M | 422.59M | 374.32M | 322.15M | 190.31M | 204.83M | 90.16M | 174.04M | 136.90M | 85.36M | 79.82M | -40.84M | 52.16M | 39.39M | 29.90M | 21.00M | 10.90M | 4.90M | 3.40M | 1.60M | 900.00K |
| EBITDA Ratio | 32.73% | 31.72% | 33.37% | 34.80% | 33.47% | 32.36% | 29.85% | 29.02% | 29.40% | 29.44% | 27.49% | 24.10% | 22.68% | 23.31% | 22.73% | 22.07% | 24.47% | 19.12% | 28.86% | 34.72% | 30.28% | 28.29% | -21.95% | 43.70% | 33.87% | 35.44% | 33.53% | 16.46% | 5.78% | 10.21% | 7.91% | 3.90% |
| Operating Income | 1.32B | 1.13B | 1.00B | 903.68M | 809.66M | 579.26M | 541.83M | 425.80M | 428.95M | 409.24M | 405.09M | 354.82M | 294.41M | 266.92M | 240.38M | 190.31M | 142.97M | 90.16M | 131.30M | 97.35M | 85.36M | 67.24M | -51.16M | 26.04M | 33.14M | 25.30M | 17.30M | 8.30M | 3.70M | 2.80M | 1.30M | 700.00K |
| Operating Income Ratio | 28.17% | 26.80% | 27.96% | 28.27% | 27.38% | 22.22% | 23.15% | 20.60% | 23.33% | 24.38% | 26.05% | 23.43% | 21.51% | 21.47% | 22.01% | 20.67% | 17.11% | 12.59% | 21.63% | 22.88% | 25.16% | 24.58% | -25.07% | 16.78% | 28.66% | 28.56% | 26.02% | 16.87% | 10.69% | 11.91% | 9.35% | 9.09% |
| Total Other Income/Expenses | -55.10M | -30.21M | -39.80M | -20.02M | -76.57M | -60.42M | -20.52M | -7.06M | 10.61M | 26.68M | 25.99M | 30.30M | 37.54M | 36.78M | 20.21M | 11.37M | 14.89M | 7.81M | 2.09M | -727.00K | -693.00K | -113.00K | 105.75M | 1.27M | 1.03M | -700.00K | -1.20M | 2.80M | 2.90M | 900.00K | 500.00K | 500.00K |
| Income Before Tax | 1.26B | 1.10B | 960.48M | 883.66M | 733.09M | 518.85M | 521.31M | 418.74M | 439.57M | 435.92M | 431.08M | 385.12M | 331.95M | 303.71M | 260.59M | 201.68M | 157.86M | 97.97M | 133.39M | 96.63M | 84.67M | 67.13M | 54.59M | 27.31M | 34.17M | 24.60M | 16.10M | 11.10M | 6.60M | 3.70M | 1.80M | 1.20M |
| Income Before Tax Ratio | 27.00% | 26.09% | 26.84% | 27.64% | 24.79% | 19.91% | 22.28% | 20.26% | 23.91% | 25.96% | 27.72% | 25.43% | 24.26% | 24.43% | 23.86% | 21.90% | 18.90% | 13.68% | 21.98% | 22.71% | 24.95% | 24.54% | 26.75% | 17.60% | 29.55% | 27.77% | 24.21% | 22.56% | 19.08% | 15.74% | 12.95% | 15.58% |
| Income Tax Expense | 243.85M | 204.11M | 181.05M | 409.16M | 111.41M | 114.26M | 205.72M | 76.46M | 87.16M | 83.03M | 85.81M | 77.99M | 77.10M | 76.72M | 70.50M | 55.24M | 47.55M | 31.67M | 45.18M | 31.84M | 27.38M | 21.40M | 17.09M | 15.68M | 11.94M | 8.50M | 5.50M | 3.60M | 2.10M | 900.00K | 600.00K | 400.00K |
| Net Income | 1.02B | 897.56M | 779.44M | 474.51M | 621.67M | 404.59M | 315.59M | 342.28M | 352.41M | 352.89M | 345.27M | 307.13M | 254.85M | 226.99M | 190.09M | 146.45M | 110.30M | 66.30M | 88.21M | 64.79M | 57.28M | 45.73M | 37.51M | 11.63M | 22.23M | 16.10M | 10.60M | 7.50M | 4.50M | 2.80M | 1.20M | 800.00K |
| Net Income Ratio | 21.79% | 21.25% | 21.78% | 14.84% | 21.02% | 15.52% | 13.49% | 16.56% | 19.17% | 21.02% | 22.20% | 20.28% | 18.62% | 18.26% | 17.40% | 15.91% | 13.20% | 9.26% | 14.53% | 15.23% | 16.88% | 16.72% | 18.38% | 7.50% | 19.22% | 18.17% | 15.94% | 15.24% | 13.01% | 11.91% | 8.63% | 10.39% |
| EPS | 6.94 | 6.12 | 5.34 | 3.27 | 4.31 | 2.83 | 2.21 | 2.42 | 2.51 | 2.51 | 2.44 | 2.15 | 1.75 | 1.49 | 1.26 | 0.97 | 0.72 | 0.43 | 0.61 | 0.47 | 0.43 | 0.35 | 0.29 | 0.09 | 0.19 | 0.14 | 0.09 | 0.06 | 0.04 | 0.04 | 0.02 | 0.02 |
| EPS Diluted | 6.92 | 6.09 | 5.30 | 3.24 | 4.27 | 2.80 | 2.19 | 2.40 | 2.49 | 2.47 | 2.39 | 2.10 | 1.71 | 1.44 | 1.23 | 0.95 | 0.70 | 0.43 | 0.58 | 0.46 | 0.41 | 0.33 | 0.28 | 0.09 | 0.17 | 0.13 | 0.09 | 0.06 | 0.04 | 0.04 | 0.02 | 0.02 |
| Weighted Avg Shares Out | 147.02M | 146.77M | 146.07M | 145.31M | 144.34M | 143.11M | 142.76M | 141.36M | 140.24M | 140.47M | 141.47M | 142.95M | 145.90M | 152.47M | 150.91M | 151.26M | 154.76M | 153.42M | 144.61M | 137.29M | 134.78M | 132.22M | 128.70M | 124.52M | 120.61M | 117.66M | 116.16M | 117.07M | 112.50M | 70.00M | 53.33M | 48.00M |
| Weighted Avg Shares Out (Dil) | 147.55M | 147.46M | 147.04M | 146.45M | 145.65M | 144.48M | 143.99M | 142.45M | 141.67M | 142.69M | 144.36M | 146.41M | 149.32M | 157.20M | 155.10M | 154.23M | 157.42M | 156.51M | 154.32M | 149.88M | 140.50M | 137.76M | 136.32M | 133.94M | 129.21M | 124.27M | 120.28M | 117.07M | 112.50M | 70.00M | 53.33M | 48.00M |
Shareholders that lost money on ResMed Inc.(RMD) should contact Levi & Korsinsky about Securities Fraud Investigation - RMD
ATTENTION RMD SHAREHOLDERS: Investors who lost money on ResMed Inc. are urged to contact Levi & Korsinsky about an ongoing investigation
ResMed (RMD) Reports Next Week: Wall Street Expects Earnings Growth
ResMed Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by ResMed (RMD)
RMD STOCK ALERT: Levi & Korsinsky Notifies ResMed Inc. Investors of an Ongoing Investigation
Levi & Korsinsky Reminds ResMed Investors of the Ongoing Investigation into Potential Violations of Securities Laws - RMD
Here's Why ResMed (RMD) is a Strong Growth Stock
Falling Knives: 3 Stocks Getting the Cold Shoulder From Analysts
ResMed: Potentially Undervalued Amid Increasing Sleep Apnea Awareness
ResMed to Report Fourth Quarter Fiscal 2024 Earnings on August 1, 2024
Source: https://incomestatements.info
Category: Stock Reports